Oral β-lactams applied to uncomplicated infections of skin and skin structures

Diagnostic Microbiology and Infectious Disease

Volumn 57, Issue 3 SUPPL., 2007, Pages

  Jacobs, Michael R ^a   Jones, Ronald N ^b,c   Giordano, Philip A ^d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JMI LABORATORIES   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ORLANDO REGIONAL MEDICAL CENTER   (United States)

Author keywords

MRSA; Staphylococcus aureus; Streptococcus pyogenes; Uncomplicated skin and skin structure infections

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFDINIR; CEFDITOREN; CEFDITOREN PIVOXIL; CEFPODOXIME PROXETIL; CEFPROZIL; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DICLOXACILLIN; DOXYCYCLINE; ERYTHROMYCIN; FLEROXACIN; LEVOFLOXACIN; LINEZOLID; LORACARBEF; MINOCYCLINE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PSEUDOMONIC ACID; UNINDEXED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SKIN INFECTION; SKIN STRUCTURE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CLINICAL TRIALS; HUMANS; METHICILLIN RESISTANCE; PRACTICE GUIDELINES; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS; STREPTOCOCCAL INFECTIONS;

EID: 33847343837     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.11.020     Document Type: Article

References (74)

1. Alos J.I., Aracil B., Oteo J., and Gomez-Garces J.L. Significant increase in the prevalence of erythromycin-resistant, clindamycin- and miocamycin-susceptible (M phenotype) Streptococcus pyogenes in Spain. J. Antimicrob. Chemother. 51 (2003) 333-337
2. Altman D.G. Practical Statistics for Medical Research (1991), Chapman & Hall, London (UK)
3. Appelbaum P.C. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 12 Suppl. 1 (2006) 16-23
4. Blackwelder W.C. "Proving the null hypothesis" in clinical trials. Control. Clin. Trials 3 (1982) 345-353
5. Blackwelder W.C., and Chang M.A. Sample size graphs for "proving the null hypothesis". Control Clin. Trials 5 (1984) 97-105
6. Bozdogan B., Appelbaum P.C., Kelly L.M., Hoellman D.B., Tambic-Andrasevic A., Drukalska L., Hryniewicz W., Hupkova H., Jacobs M.R., Kolman J., Konkoly-Thege M., Miciuleviciene J., Pana M., Setchanova L., Trupl J., and Urbaskova P. Activity of telithromycin compared with seven other agents against 1,039 Streptococcus pyogenes pediatric isolates from ten centers in central and eastern Europe. Clin. Microbiol. Infect. 9 (2003) 741-745
7. Bucko A.D., Hunt B.J., Kidd S.L., and Hom R. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clin. Ther. 24 (2002) 1134-1147
8. Buxbaum A., Forsthuber S., Graninger W., and Georgopoulos A. Comparative activity of telithromycin against typical community-acquired respiratory pathogens. J. Antimicrob. Chemother. 52 (2003) 371-374
9. Calderon-Jaimes E., Espinosa de los Monteros L.E., and Avila-Beltran R. Epidemiology of drug resistance: the case of Staphylococcus aureus and coagulase-negative staphylococci infections. Salud Publica Mex. 44 (2002) 108-112
10. Ceclor. Physician's Desk Reference (2004), Thompson PDR, Montvale (NJ) 1829-1831
11. Ceftin. Physicians' Desk Reference (2005), Thompson PDR, Montvale (NJ) 1450-1454
12. Cefzil. Physicians' Desk Reference (2005), Thompson PDR, Montvale (NJ) 1037-1039
13. Christiansen K.J., Bell J.M., Turnidge J.D., and Jones R.N. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY Program, 1999 to 2001. Antimicrob. Agents Chemother. 48 (2004) 2049-2055
14. CLSI. Clinical and Laboratory Standards Institute. M100-S16, Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement (2006), CLSI, Wayne (PA)
15. Coll P.F., Ausina V.R., Vernis J.V., Mirelis B.O., and Prats G.P. Exogenous thymidine and reversal of the inhibitory effect of sulfamethoxazole-trimethoprim on streptococci. Eur. J. Clin. Microbiol. 3 (1984) 424-426
16. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26 (1998) 1-10 (quiz 11-12)
17. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 17 (2003) 479-501
18. Darmstadt G.L. Oral antibiotic therapy for uncomplicated bacterial skin infections in children. Pediatr. Infect. Dis. J. 16 (1997) 227-240
19. Diekema D.J., Pfaller M.A., Schmitz F.J., Smayevsky J., Bell J., Jones R.N., and Beach M. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32 Suppl. 2 (2001) S114-S132
20. Doern G.V., and Brown S.D. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J. Infect. 48 (2004) 56-65
21. Duricef. Physicians' Desk Reference (2005), Thompson PDR, Montvale (NJ) 3291
22. Duricef Package Insert (2005), Warner Chilcott, Inc., Rockaway (NJ)
23. Eliopoulos G.M., and Wennersten C.B. In vitro activity of trimethoprim alone compared with trimethoprim-sulfamethoxazole and other antimicrobials against bacterial species associated with upper respiratory tract infections. Diagn. Microbiol. Infect Dis. 29 (1997) 33-38
24. Ellenberg S.S., and Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases. Ann. Intern. Med. 133 (2000) 464-470
25. EMEA. Committee for Medicinal Products for Human Use (CHMP): guideline on the choice of the non-inferiority margin (2006). http://www.emea.europa.eu/pdfs/human/ewp/215899en.pdf (Accessed October 2006)
26. Fleisher G.R., Wilmott C.M., and Campos J.M. Amoxicillin combined with clavulanic acid for the treatment of soft tissue infections in children. Antimicrob. Agents Chemother. 24 (1983) 679-681
27. Fritsche T.R., and Jones R.N. Importance of understanding pharmacokinetic/pharmacodynamic principles in the emergence of resistances, including community-associated Staphylococcus aureus. J. Durgs Dermatol. 4 (2005) s4-s8
28. Fritsche T.R., Sader H.S., and Jones R.N. Comparative activity and spectrum of broad-spectrum β-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002). Diagn. Microbiol. Infect Dis. 47 (2003) 435-440
29. Giordano P.A., Elston D., Akinlade B.K., Weber K., Nortario G.F., Busman T.A., Cifaldi M., and Nilius A.M. Cefdinir versus cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults. Curr. Med. Res. Opin. 22 (2006) 2419-2428
30. Gravenkemper C.F., Bennett J.V., Brodie J.L., and Kirby W.M. Dicloxacillin. In vitro and pharmacologic comparisons with oxacillin and cloxacillin. Arch. Intern. Med. 116 (1965) 340-345
31. Grayson M.L. The treatment triangle for staphylococcal infections. N. Engl. J. Med. 355 (2006) 724-727
32. Hanfling M.J., Hausinger S.A., and Squires J. Loracarbef vs. cefaclor in pediatric skin and skin structure infections. Pediatr. Infect. Dis. J. 11 (1992) S27-S30
33. Hedrick J. Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr. Drugs 5 Suppl. 1 (2003) 35-46
34. Hoban D., Waites K., and Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT Surveillance Study. Diagn. Microbiol. Infect. Dis. 45 (2003) 251-259
35. Hsueh P.R., Teng L.J., Lee C.M., Huang W.K., Wu T.L., Wan J.H., Yang D., Shyr J.M., Chuang Y.C., Yan J.J., Lu J.J., Wu J.J., Ko W.C., Chang F.Y., Yang Y.C., Lau Y.J., Liu Y.C., Leu H.S., Liu C.Y., and Luh K.T. Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data. Antimicrob. Agents Chemother. 47 (2003) 2152-2157
36. Hung H.M., Wang S.J., and O'Neill R. A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials. Biom. Z. 47 (2005) 28-36 (discussion 99-107)
37. Jennings M.B., McCarty J.M., Scheffler N.M., Puopolo A.D., and Rothermel C.D. Comparison of azithromycin and cefadroxil for the treatment of uncomplicated skin and skin structure infections. Cutis 72 (2003) 240-244
38. Jones M.E., Draghi M.E., Thornsberry C., Karlowsky J.A., Sahm D.F., and Wenzel R.P. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American Surveillance study (2000-2002). Ann. Clin. Microbiol. Antimicrob. 3 (2004) 14
39. Jones M.E., Karlowsky J.A., Draghi D.C., Thornsberry C., Sahm D.F., and Bradley J.S. Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients. Eur. J. Clin. Microbiol. Infect. Dis. 23 (2004) 445-455
40. Jones R.N., Deshpande L.M., Nilius A., Akinlade B., and Notario G. Molecular characterization of S. aureus (SA) isolates from a contemporary (2005) clinical trial of uncomplicated skin and skin structure infections (uSSSI). Abstr L-1202 46th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA (2006)
41. Kaplan S.L., Afghani B., Lopez P., Wu E., Fleishaker D., Edge-Padbury B., Naberhuis-Stehouwer S., and Bruss J.B. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr. Infect. Dis. J. 22 (2003) S178-S185
42. Katz K.C., McGeer A.J., Duncan C.L., Ashi-Sulaiman A., Willey B.M., Sarabia A., McCann J., Pong-Porter S., Rzayev Y., de Azavedo J.S., and Low D.E. Emergence of macrolide resistance in throat culture isolates of group A streptococci in Ontario, Canada, in 2001. Antimicrob. Agents Chemother. 47 (2003) 2370-2372
43. Keflex. Physicians' Desk Reference (2005), Thompson PDR, Montvale (NJ) 1871-1873
44. Kim H.B., Jang H.C., Nam H.J., Lee Y.S., Kim B.S., Park W.B., Lee K.D., Choi Y.J., Park S.W., Oh M.D., Kim E.C., and Choe K.W. In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: a nationwide survey. Antimicrob. Agents Chemother. 48 (2004) 1124-1127
45. Laube S., and Farrell A.M. Bacterial skin infections in the elderly: diagnosis and treatment. Drugs Aging 19 (2002) 331-342
46. Lee M.C., Rios A.M., Aten M.F., Mejias A., Cavuoti D., McCracken Jr. G.H., and Hardy R.D. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr. Infect. Dis. J. 23 (2004) 123-127
47. Liebowitz L.D., Slabbert M., and Huisamen A. National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents. J. Clin. Pathol. 56 (2003) 344-347
48. Lin D., and Brittain E. FDA Anti-Infective Drugs Advisory Committee, February 19, 2002 (2002). http://www.fda.gov/ohrms/dockets/ac/02/slides/3837s1.htm (Accessed October 2006)
49. Marchant C.D., Carlin S.A., Johnson C.E., and Shurin P.A. Measuring the comparative efficacy of antibacterial agents for acute otitis media: the "Pollyanna phenomenon". J. Pediatr. 120 (1992) 72-77
50. Mendes C., Marin M.E., Quinones F., Sifuentes-Osornio J., Siller C.C., Castanheira M., Zoccoli C.M., Lopez H., Sucari A., Rossi F., Angulo G.B., Segura A.J., Starling C., Mimica I., and Felmingham D. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT Surveillance Study (1999-2000). Braz. J. Infect. Dis. 7 (2003) 44-61
51. Montero L. A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections. J. Antimicrob. Chemother. 37 Suppl (1996) 125-131
52. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., and Talan D.A. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355 (2006) 666-674
53. Nolen T. Comparative studies of cefprozil in the management of skin and soft-tissue infections. Eur. J. Clin. Microbiol. Infect. Dis. 13 (1994) 866-871
54. Omnicef. Physicians' Desk Reference (2005), Thompson PDR, Montvale (NJ) 506-511
55. Page M.G. Anti-MRSA beta-lactams in development. Curr. Opin. Pharmacol. 6 (2006) 480-485
56. Parish L.C., Routh H.B., Miskin B., Fidelholtz J., Werschler P., Heyd A., Haverstock D., and Church D. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int. J. Clin. Pract. 54 (2000) 497-503
57. Powers R.D. Open trial of oral fleroxacin versus amoxicillin/clavulanate in the treatment of infections of skin and soft tissue. Am. J. Med. 94 (1993) 155S-158S
58. Rosen T. Update on treating uncomplicated skin and skin structure infections. J. Durgs Dermatol. 4 (2005) s9-s14
59. SISA. Simple interactive statistical analysis: sample size (2006). http://home.clara.net/sisa/samsize.htm (Accessed October 2006)
60. Smith J.W., and Nichols R.L. Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections. Am. J. Med. 94 (1993) 150S-154S
61. Spectracef. Physicians' Desk Reference (2005), Thompson PDR, Montvale (NJ) 2824-2827
62. Stevens D.L., Pien F., and Drehobl M. Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections. Diagn. Microbiol. Infect. Dis. 16 (1993) 123-129
63. Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J., Gorbach S.L., Hirschmann J.V., Kaplan E.L., Montoya J.G., and Wade J.C. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41 (2005) 1373-1406
64. Stulberg D.L., Penrod M.A., and Blatny R.A. Common bacterial skin infections. Am. Fam. Phys. 66 (2002) 119-124
65. Tack K.J., Keyserling C.H., McCarty J., and Hedrick J.A. Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group. Antimicrob. Agents Chemother. 41 (1997) 739-742
66. Tack K.J., Littlejohn T.W., Mailloux G., Wolf M.M., and Keyserling C.H. Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group. Clin. Ther. 20 (1998) 244-256
67. Tassler H. Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infections. Am. J. Med. 94 (1993) 159S-165S
68. Temple R.J. FDA Anti-Infective Drugs Advisory Committee, February 19, 2002 (2002). http://www.fda.gov/ohrms/dockets/ac/02/slides/3837s1.htm (Accessed October 2006)
69. Temple R., and Ellenberg S.S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann. Intern. Med. 133 (2000) 455-463
70. Tramer M.R., Reynolds D.J., Moore R.A., and McQuay H.J. When placebo controlled trials are essential and equivalence trials are inadequate. BMJ 317 (1998) 875-880
71. Vandenesch F., Naimi T., Enright M.C., Lina G., Nimmo G.R., Heffernan H., Liassine N., Bes M., Greenland T., Reverdy M.E., and Etienne J. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg. Infect. Dis. 9 (2003) 978-984
72. Vantin. Physicians' Desk Reference (2005), Thompson PDR, Montvale (NJ) 2758-2762
73. Waites K., and Brown S. Antimicrobial resistance among isolates of respiratory tract infection pathogens from the Southern United States: data from the PROTEKT US Surveillance Program 2000/2001. South Med. J. 96 (2003) 974-985
74. Wible K., Tregnaghi M., Bruss J., Fleishaker D., Naberhuis-Stehouwer S., and Hilty M. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr. Infect. Dis. J. 22 (2003) 315-323